胰高糖素样肽-1受体激动剂与胰腺的那些事  

Glucagon-like Peptide 1 Receptor Agonists and Pancreatic Safety

作　　者：丁露 肖新华 DING Lu;Xiao Xin-hua(Department of Endocrinology,Key Laboratory of Endocrinology of National Health Commission,The Translational Medicine Center of PUMCH,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China)

机构地区：[1]中国医学科学院,北京协和医学院,北京协和医院内分泌科,卫建委内分泌重点实验室,协和转化医学中心,北京100730

出　　处：《药品评价》2020年第S01期53-56,共4页Drug Evaluation

基　　金：国家自然科学基金(Nos.81870579,81870545,81170736,81570715);北京市自然科学基金(Nos.7202163,7172169);国家重点研发计划(Nos.2018YFC2001100,2017YFC1309603)。

摘　　要：胰高糖素样肽1受体激动剂(glucagon-like peptide 1 receptor agonist,GLP-1 RA)在2型糖尿病(type 2 diabetes mellitus,T2DM)治疗领域得到了广泛的应用。2006年一项关于艾塞那肽引起胰腺炎的病例报道,引起了人们对GLP-1 RA胰腺安全性的质疑。然而,由于糖尿病患者发生胰腺癌和胰腺炎的风险均高于普通人群,且胰腺癌和胰腺炎也会导致糖尿病发生,这些“证据”一直饱受争议。目前,GLP-1 RA这一类药物因降糖疗效可靠,整体安全性良好,并具有减轻体重、降低收缩压、改善血脂谱等降糖外获益,其在T2DM指南中的地位不断得到提升。为进一步系统评估GLP-1 RA的胰腺安全性,本文将全面回顾GLP-1RA有关胰腺安全性的证据。Glucagon-like peptide 1 receptor agonists(GLP-1RA)is widely applied as in the treatment of type 2 diabetes mellitus.A case report published in 2006 that exenatide induced pancreatitis has brought numerous disputes about the safety of GLP-1RA in the pancreas.However,due to a higher risk of pancreatic cancer and pancreatitis in diabetic patients,and the fact that pancreatic cancer and pancreatitis cause diabetes,these"evidences"have been controversial.Now,the status of GLP-1RA has been improving constantly in the T2DM guidelines with its reliable hypoglycemic efficacy,safety,and other benefits such as weight loss,lowering systolic blood pressure,and improving blood lipid profile.To further evaluate the pancreatic safety of GLP-1RA systematically,this review summarized the evidence about the pancreatic safety of GLP-1RA.

关 键 词：胰高糖素样肽1受体激动剂 胰腺安全性 糖尿病 降糖 

分 类 号：R587.1[医药卫生—内分泌]